financetom
Business
financetom
/
Business
/
Okta Fiscal Q3 Non-GAAP Earnings, Revenue Rise; Fiscal 2025 Outlook Raised; Shares Surge After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Okta Fiscal Q3 Non-GAAP Earnings, Revenue Rise; Fiscal 2025 Outlook Raised; Shares Surge After Hours
Dec 3, 2024 1:53 PM

04:36 PM EST, 12/03/2024 (MT Newswires) -- Okta ( OKTA ) reported fiscal Q3 non-GAAP earnings late Tuesday of $0.67 per diluted share, up from $0.44 a year earlier.

Analysts surveyed by FactSet expected $0.58.

Revenue for the quarter ended Oct. 31 was $665 million, up from $584 million a year earlier.

Analysts surveyed by FactSet expected $649.7 million.

The company said it expects fiscal Q4 non-GAAP diluted EPS of $0.73 to $0.74 on revenue of $667 million to $669 million. Analysts surveyed by FactSet expect non-GAAP EPS of $0.67 on revenue of $651.3 million.

Okta ( OKTA ) said it expects fiscal 2025 non-GAAP diluted EPS of $2.75 to $2.76, versus the prior outlook of $2.58 to $2.63. Analysts surveyed by FactSet expect $2.61. The company expects revenue for the year of $2.595 billion to $2.597 billion, versus previous guidance of about $2.56 billion to $2.57 billion. Analysts surveyed by FactSet expect $2.56 billion.

Shares of Okta ( OKTA ) surged past 19% in recent after-hours activity.

Price: 97.35, Change: +15.64, Percent Change: +19.14

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
LB Pharmaceuticals eyes $322 million valuation in biotech IPO amid sector drought
LB Pharmaceuticals eyes $322 million valuation in biotech IPO amid sector drought
Sep 8, 2025
Sept 8 (Reuters) - Cash-strapped drug developer LB Pharmaceuticals said on Monday it was aiming for a valuation of up to $321.6 million in its New York initial public offering, potentially setting up the first sizable U.S. biotech flotation in months. WHY IT'S IMPORTANT Biotech listings - historically a key driver of U.S. healthcare listings - have slumped this year...
Update On Strathcona; National Bank Comments as the
Update On Strathcona; National Bank Comments as the "SCR MEG Saga Continues"
Sep 8, 2025
10:39 AM EDT, 09/08/2025 (MT Newswires) -- (Adds share price update and National Bank commentary in the third paragraph) Strathcona Resources ( STHRF ) on Monday increased its offer to acquire all of MEG Energy's ( MEGEF ) common shares it does not already own for 0.80 of a Strathcona common share per MEG share. Its previous offer was for...
DuPont Wins Trade Ruling to Block China's Dawnsens New-Materials From US Market in Tyvek Case
DuPont Wins Trade Ruling to Block China's Dawnsens New-Materials From US Market in Tyvek Case
Sep 8, 2025
10:29 AM EDT, 09/08/2025 (MT Newswires) -- DuPont de Nemours ( DD ) won a US International Trade Commission ruling barring Dawnsens New-Materials from selling or importing certain materials and products related to DuPont's ( DD ) Tyvek products into the US for 10 years. The ITC approved a voluntary consent order from Dawnsens, DuPont ( DD ) said Monday...
Market Chatter: Hewlett Packard Enterprise Launches Bond Sale
Market Chatter: Hewlett Packard Enterprise Launches Bond Sale
Sep 8, 2025
10:32 AM EDT, 09/08/2025 (MT Newswires) -- Hewlett Packard Enterprise ( HPE ) is selling investment grade bonds to help refinance debt tied to its Juniper Networks acquisition, Bloomberg reported Monday, citing a person familiar with the matter. The four-part, dollar-denominated offering includes a mix of floating-rate and fixed-rate notes, with the longest maturity at five years, according to the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved